Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 15/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106667 | 0.90 | ADORA3 (0.48) | TRPV1ADORA3ADORA2AADORA1LMNA | |
| SCHEMBL5109545 | 0.87 | TRPV1 (0.46) | TRPV1ADORA3ADORA2AADORA1ALDH1A1 | |
| SCHEMBL5116505 | 0.84 | TRPV1 (0.68) | TRPV1 | |
| SCHEMBL5106220 | 0.82 | TRPV1 (0.59) | TRPV1ADORA3ADORA2AADORA1 | |
| SCHEMBL14311006 | 0.79 | ADORA3 (0.43) | TRPV1ADORA3ADORA2AADORA1ALDH1A1 | |
| SCHEMBL5112189 | 0.78 | TRPV1 (0.47) | TRPV1ADORA3ADORA2AADORA1ALDH1A1 | |
| SCHEMBL3931651 | 0.78 | ADORA3 (0.77) | TRPV1ADORA3ADORA2AADORA1 | |
| SCHEMBL5108152 | 0.78 | ADORA2A (0.40) | TRPV1ADORA3ADORA2AADORA1ALDH1A1 | |
| SCHEMBL5109919 | 0.78 | TRPV1 (0.72) | TRPV1 | |
| SCHEMBL5110748 | 0.77 | KDR (0.48) | TRPV1ADORA3ADORA2AADORA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008005303-A2 | THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080004253-A1 | Thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | US | disclosed |
| US-20080004253-A1 | Thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | US | disclosed |
| US-20080004253-A1 | Thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004253-A1 | Thiazolopyrimidine modulators of TRPV1 | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885ADORA3 819/4885ADORA2A 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.